Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

Completed · Phase 3 · Has a placebo group

Conditions studied: Peanut Allergy

In brief

The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.

Key facts

Study ID
NCT02635776
Run by
Aimmune Therapeutics, Inc.
People needed
555
Starts
2015-12-22
Expected to finish
2018-07-02
Last updated by the study team
2022-03-17

Who can join

Age: 4 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.